December 16, 2025
Aurobindo Receives FDA Approval for Cariprazine Capsules, 1.5 mg, 3 mg, and 6 mg
East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Cariprazine Capsules, 1.5 mg, 3 mg, and 6 mg. Aurobindo Pharma’s Cariprazine Capsules are an AB-rated generic equivalent to the reference listed drug (RLD), Vraylar Capsules manufactured by AbbVie Inc. Cariprazine Capsules […]
